Insider Buying: DarioHealth (NASDAQ:DRIO) Director Acquires $99,999.90 in Stock

DarioHealth Corp. (NASDAQ:DRIO) Director Dennis Matheis purchased 14,430 shares of DarioHealth stock in a transaction dated Thursday, July 23rd. The stock was bought at an average cost of $6.93 per share, with a total value of $99,999.90. Following the completion of the transaction, the director directly owned 43,026 shares of the company’s stock, valued at $298,170.18. This represents a 50.46% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

DarioHealth Stock Up 0.3%

DRIO traded up $0.02 on Tuesday, reaching $7.49. 8,219 shares of the company traded hands, compared to its average volume of 14,013. The stock’s 50 day moving average price is $7.19 and its 200-day moving average price is $8.67. DarioHealth Corp. has a 52-week low of $5.84 and a 52-week high of $17.74. The company has a market cap of $54.98 million, a price-to-earnings ratio of -0.84 and a beta of 1.09. The company has a debt-to-equity ratio of 0.50, a current ratio of 3.07 and a quick ratio of 2.62.

Institutional Trading of DarioHealth

Large investors have recently modified their holdings of the company. XTX Topco Ltd raised its holdings in DarioHealth by 229.0% in the 2nd quarter. XTX Topco Ltd now owns 62,511 shares of the company’s stock worth $42,000 after acquiring an additional 43,513 shares during the period. Geode Capital Management LLC lifted its position in DarioHealth by 167.9% during the 4th quarter. Geode Capital Management LLC now owns 49,567 shares of the company’s stock worth $564,000 after acquiring an additional 31,063 shares during the last quarter. Finally, Kestra Advisory Services LLC bought a new stake in DarioHealth during the fourth quarter valued at about $35,000. 33.39% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several research firms have recently commented on DRIO. Stifel Nicolaus restated a “buy” rating and set a $10.00 price target on shares of DarioHealth in a report on Thursday, May 14th. TD Cowen reiterated a “hold” rating and set a $11.00 price objective on shares of DarioHealth in a report on Wednesday, May 13th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of DarioHealth in a research report on Friday, July 10th. One analyst has rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $10.50.

DarioHealth Company Profile

DarioHealth (NASDAQ:DRIO) is a digital health company specializing in chronic disease management through a smartphone-based care platform. Its core solution combines connected devices—such as glucose meters, blood pressure monitors and smart scales—with real-time data analytics and personalized coaching. The platform is designed to support individuals living with diabetes, hypertension, weight management challenges and other cardiometabolic conditions, offering continuous monitoring, tailored insights and behavioral nudges aimed at improving clinical outcomes.

The Dario platform integrates artificial intelligence and machine learning to deliver personalized guidance and education.